Squamous Cell Carcinoma Pipeline Review, H2 2012


#146052

456pages

Global Markets Direct

$ 2000

In Stock


Squamous Cell Carcinoma Pipeline Review, H2 2012

Global Markets Directs, 'Squamous Cell Carcinoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Squamous Cell Carcinoma.
  • A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 23
List of Figures 25
Introduction 26
Global Markets Direct Report Coverage 26
Squamous Cell Carcinoma Overview 27
Therapeutics Development 28
An Overview of Pipeline Products for Squamous Cell Carcinoma 28
Squamous Cell Carcinoma Therapeutics under Development by Companies 30
Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 33
Late Stage Products 41
Comparative Analysis 41
Mid Clinical Stage Products 42
Comparative Analysis 42
Early Clinical Stage Products 43
Comparative Analysis 43
Discovery and Pre-Clinical Stage Products 44
Comparative Analysis 44
Squamous Cell Carcinoma Therapeutics Products under Development by Companies 45
Squamous Cell Carcinoma Therapeutics Products under Investigation by Universities/Institutes 48
Companies Involved in Squamous Cell Carcinoma Therapeutics Development 58
Boehringer Ingelheim GmbH 58
F. Hoffmann-La Roche Ltd. 59
Shionogi & Co., Ltd. 60
Amgen Inc. 61
Sanofi-Aventis 62
Eli Lilly and Company 63
Genentech, Inc. 64
YM BioSciences Inc. 65
Celltrion, Inc. 66
Millennium Pharmaceuticals, Inc. 67
Eisai Co., Ltd. 68
Pfizer Inc. 69
Takara Holdings Inc. 70
Yakult Honsha Co., Ltd. 71
CEL-SCI Corporation 72
Merck KGaA 73
Idera Pharmaceuticals, Inc. 74
NexMed, Inc. 75
Clinuvel Pharmaceuticals Limited 76
Oncolytics Biotech Inc. 77
Oncothyreon Inc 78
Jennerex Biotherapeutics, Inc. 79
Omeros Corporation 80
Cellceutix Corporation 81
Genelux Corporation 82
IRX Therapeutics, Inc. 83
Eurofarma 84
Biotech Pharmaceuticals Co., Ltd. 85
Squamous Cell Carcinoma Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Combination Products 87
Assessment by Route of Administration 88
Assessment by Molecule Type 90
Drug Profiles 93
IMO-2055Rx - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Alimta + IV Dexamethasone - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Cisplatin + Gemcitabine + Docetaxel - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 119
Alimta + Eloxatin - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
erlotinib hydrochloride - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Erlotinib + Docetaxel + Radiation Therapy - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
cetuximab - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Temsirolimus + Paclitaxel + Carboplatin - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Cisplatin + Cetuximab + Temsirolimus - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 131
Fludarabine + Radiation Therapy - Drug Profile 195
Product Description 195
Mechanism of Action 195
R&D Progress 195
Pemetrexed + Cetuximab + Carboplatin - Drug Profile 196
Product Description 196
Mechanism of Action 196
R&D Progress 197
Pemetrexed + Cetuximab + Cisplatin - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 198
RG-7160 - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 200
Cisplatin + Carboplatin + Radiotherapy - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
IMC-A12 + Erbitux - Drug Profile 204
Product Description 204
Mechanism of Action 204
R&D Progress 204
Tarceva + Cisplatin + Radiation Therapy - Drug Profile 244
Product Description 244
Mechanism of Action 244
R&D Progress 244
Cisplatin + Erlotinib + Radiation Therapy - Drug Profile 246
Product Description 246
Mechanism of Action 246
R&D Progress 246
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 248
Product Description 248
Mechanism of Action 248
R&D Progress 248
PX-866 + Docetaxel - Drug Profile 250
Product Description 250
Mechanism of Action 250
R&D Progress 250
Vorinostat + Cisplatin + Radiation Therapy - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 251
Carboplatin + TS-1 - Drug Profile 252
Product Description 252
Mechanism of Action 252
R&D Progress 252
Cisplatin + Gemcitabine - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
Cetuximab + Oxaliplatin + Fluorouracil - Drug Profile 254
Product Description 254
Mechanism of Action 254
R&D Progress 255
Cytosine Arabinoside + Cisplatin - Drug Profile 256
Product Description 256
Mechanism of Action 256
R&D Progress 256
Docetaxel + 5-Fluorouracil + Cisplatin - Drug Profile 257
Product Description 257
Mechanism of Action 257
R&D Progress 258
cetuximab - Drug Profile 260
Product Description 260
Mechanism of Action 260
R&D Progress 260
nimotuzumab - Drug Profile 338
Product Description 338
Mechanism of Action 338
R&D Progress 338
Carboplatin + S-1 - Drug Profile 339
Product Description 339
Mechanism of Action 339
R&D Progress 339
Temsirolimus + Cisplatin + Cetuximab - Drug Profile 340
Product Description 340
Mechanism of Action 340
R&D Progress 340
vandetanib - Drug Profile 386
Product Description 386
Mechanism of Action 386
R&D Progress 386
Cabazitaxel + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 387
Product Description 387
Mechanism of Action 387
R&D Progress 387
Boanmycin Hydrochloride + Docetaxel - Drug Profile 409
Product Description 409
Mechanism of Action 409
R&D Progress 409
lapatinib ditosylate - Drug Profile 410
Product Description 410
Mechanism of Action 410
R&D Progress 410
Squamous Cell Carcinoma Therapeutics Drug Profile Updates 411
Squamous Cell Carcinoma Therapeutics Discontinued Products 435
Squamous Cell Carcinoma Therapeutics - Dormant Products 437
Squamous Cell Carcinoma Product Development Milestones 447
Featured News & Press Releases 447
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 447
Jul 06, 2012: Navidea To Present Data From Lymphoseek Program At Upcoming Upcoming Scientific Meetings In July 448
Jun 02, 2012: Oncothyreon Provides Update On PX-866 Phase II Program 448
Dec 07, 2011: CEL- SCI Updates Phase III Clinical Activities For Multikine 449
Nov 13, 2011: Oncothyreon Presents Data From Phase I/II Trials Of PX-866 In Combination With Docetaxel At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 450
Nov 13, 2011: Oncothyreon Presents Data From Phase I/II Trials Of PX-866 In Combination With Cetuximab At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 451
Nov 02, 2011: CEL- SCI Updates Phase III Clinical Activities For Investigational Cancer Therapy Multikine 452
Aug 23, 2011: Symphogen Initiates Phase II Trial Of Sym004 EGFR Antibody Mixture In Patients With Squamous Cell Carcinoma Of Head And Neck Cancer 453
Jul 15, 2011: PharmaEngine Presents Pre-clinical Study Of PEP02 For Four Xenograft Models In Human Lung Tumors At 14th World Conference On Lung Cancer 453
Jul 07, 2011: Idera Pharmaceuticals Provides Update On IMO-2055 Combination Therapy In Phase II Carcinoma Study 454

Appendix 455
Methodology 455
Coverage 455
Secondary Research 455
Primary Research 455
Expert Panel Validation 455
Contact Us 456
Disclaimer 456

Number of Products Under Development for Squamous Cell Carcinoma, H2 2012 28
Products under Development for Squamous Cell Carcinoma Comparative Analysis, H2 2012 29
Number of Products under Development by Companies, H2 2012 31
Number of Products under Development by Companies, H2 2012 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 40
Comparative Analysis by Late Stage Development, H2 2012 41
Comparative Analysis by Mid Clinical Stage Development, H2 2012 42
Comparative Analysis by Early Clinical Stage Development, H2 2012 43
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 44
Products under Development by Companies, H2 2012 45
Products under Development by Companies, H2 2012 (Contd..1) 46
Products under Development by Companies, H2 2012 (Contd..2) 47
Products under Investigation by Universities/Institutes, H2 2012 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 57
Boehringer Ingelheim GmbH, H2 2012 58
F. Hoffmann-La Roche Ltd., H2 2012 59
Shionogi & Co., Ltd., H2 2012 60
Amgen Inc., H2 2012 61
Sanofi-Aventis, H2 2012 62
Eli Lilly and Company, H2 2012 63
Genentech, Inc., H2 2012 64
YM BioSciences Inc., H2 2012 65
Celltrion, Inc., H2 2012 66
Millennium Pharmaceuticals, Inc., H2 2012 67
Eisai Co., Ltd., H2 2012 68
Pfizer Inc., H2 2012 69
Takara Holdings Inc., H2 2012 70
Yakult Honsha Co., Ltd., H2 2012 71
CEL-SCI Corporation, H2 2012 72
Merck KGaA, H2 2012 73
Idera Pharmaceuticals, Inc., H2 2012 74
NexMed, Inc., H2 2012 75
Clinuvel Pharmaceuticals Limited, H2 2012 76
Oncolytics Biotech Inc., H2 2012 77
Oncothyreon Inc, H2 2012 78
Jennerex Biotherapeutics, Inc., H2 2012 79
Omeros Corporation, H2 2012 80
Cellceutix Corporation, H2 2012 81
Genelux Corporation, H2 2012 82
IRX Therapeutics, Inc., H2 2012 83
Eurofarma, H2 2012 84
Biotech Pharmaceuticals Co., Ltd., H2 2012 85
Assessment by Monotherapy Products, H2 2012 86
Assessment by Combination Products, H2 2012 87
Assessment by Stage and Route of Administration, H2 2012 89
Assessment by Stage and Molecule Type, H2 2012 92
Squamous Cell Carcinoma Therapeutics Drug Profile Updates 411
Squamous Cell Carcinoma Therapeutics Discontinued Products 435
Squamous Cell Carcinoma Therapeutics Discontinued Products (Contd..1) 436
Squamous Cell Carcinoma Therapeutics Dormant Products 437
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..1) 438
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..2) 439
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..3) 440
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..4) 441
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..5) 442
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..6) 443
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..7) 444
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..8) 445
Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..9) 446
Number of Products under Development for Squamous Cell Carcinoma, H2 2012 28
Products under Development for Squamous Cell Carcinoma Comparative Analysis, H2 2012 29
Products under Development by Companies, H2 2012 30
Products under Investigation by Universities/Institutes, H2 2012 33
Late Stage Products, H2 2012 41
Mid Clinical Stage Products, H2 2012 42
Early Clinical Stage Products, H2 2012 43
Discovery and Pre-Clinical Stage Products, H2 2012 44
Assessment by Monotherapy Products, H2 2012 86
Assessment by Combination Products, H2 2012 87
Assessment by Route of Administration, H2 2012 88
Assessment by Stage and Route of Administration, H2 2012 89
Assessment by Molecule Type, H2 2012 90
Assessment by Stage and Molecule Type, H2 2012 91